NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio LLC, a biopharmaceutical company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders, today announced the hiring of Michael Greco, JD to lead the Company’s legal function. In this role, Mr. Greco will have responsibility for Rallybio’s legal, intellectual property, compliance and governance activities.
“Having worked with Mike for many years, we are delighted that he has joined the Rallybio team,” said Rallybio co-founder, Dr. Martin Mackay. “Mike’s expertise and experience with corporate transactions and financings will be critical for Rallybio as we continue to advance the development of our product candidates, further expand our portfolio and transition into a clinical stage company.”
Mr. Greco brings more than 20 years of legal experience to Rallybio. He previously served as the first General Counsel of SpringWorks Therapeutics, where he was responsible for the Company’s legal, compliance and intellectual property functions, and supported the Company’s initial public offering and business development activities. Prior to SpringWorks, Mr. Greco was Senior Vice President of Law and Corporate Secretary of Alexion Pharmaceuticals. During his tenure at Alexion, he assumed positions of increasing responsibility in the legal department and, in his most recent role, was responsible for overseeing corporate governance initiatives, public reporting, and corporate transactions, while leading the department’s corporate, R&D, business development and employment law teams. Prior to Alexion, Mr. Greco was in private practice.
Commenting on his appointment, Mr. Greco said, “My colleagues at Rallybio have a reputation for discovering and commercializing medical and scientific solutions for those who need them most, and I could not be more excited to join such a talented and enthusiastic team of industry leaders. I look forward to applying my legal experience to support Rallybio’s important work of advancing its programs and expanding its pipeline.”
Mr. Greco received his JD from Suffolk University Law School, and a BS from the United States Military Academy, West Point.
Rallybio is focused on identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. The founders of the company – Martin Mackay, PhD, Stephen Uden, MD, and Jeffrey Fryer, CPA – are seasoned leaders from the biopharma industry with a wide breadth of research, development, and financial experience. Named by FierceBiotech as one of its “Fierce 15” Biotech Companies of 2018, the company was recognized as being among “the most promising private biotech startups”. Rallybio is headquartered in New Haven, Connecticut with an additional location at the University of Connecticut’s Technology Incubation Program in Farmington, Connecticut. For more information, please visit www.rallybio.com.